297 related articles for article (PubMed ID: 16252235)
1. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.
Ai M; Heeger S; Bartels CF; Schelling DK;
Am J Hum Genet; 2005 Nov; 77(5):741-53. PubMed ID: 16252235
[TBL] [Abstract][Full Text] [Related]
2. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
Levasseur R; Lacombe D; de Vernejoul MC
Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
[TBL] [Abstract][Full Text] [Related]
3. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
Gong Y; Slee RB; Fukai N; Rawadi G; Roman-Roman S; Reginato AM; Wang H; Cundy T; Glorieux FH; Lev D; Zacharin M; Oexle K; Marcelino J; Suwairi W; Heeger S; Sabatakos G; Apte S; Adkins WN; Allgrove J; Arslan-Kirchner M; Batch JA; Beighton P; Black GC; Boles RG; Boon LM; Borrone C; Brunner HG; Carle GF; Dallapiccola B; De Paepe A; Floege B; Halfhide ML; Hall B; Hennekam RC; Hirose T; Jans A; Jüppner H; Kim CA; Keppler-Noreuil K; Kohlschuetter A; LaCombe D; Lambert M; Lemyre E; Letteboer T; Peltonen L; Ramesar RS; Romanengo M; Somer H; Steichen-Gersdorf E; Steinmann B; Sullivan B; Superti-Furga A; Swoboda W; van den Boogaard MJ; Van Hul W; Vikkula M; Votruba M; Zabel B; Garcia T; Baron R; Olsen BR; Warman ML;
Cell; 2001 Nov; 107(4):513-23. PubMed ID: 11719191
[TBL] [Abstract][Full Text] [Related]
4. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation.
Barros ER; Dias da Silva MR; Kunii IS; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2008 Aug; 21(8):811-8. PubMed ID: 18825883
[TBL] [Abstract][Full Text] [Related]
5. Novel Homozygous LRP5 Mutations in Mexican Patients with Osteoporosis-Pseudoglioma Syndrome.
Astiazarán MC; Cervantes-Sodi M; Rebolledo-Enríquez E; Chacón-Camacho O; Villegas V; Zenteno JC
Genet Test Mol Biomarkers; 2017 Dec; 21(12):742-746. PubMed ID: 29131652
[TBL] [Abstract][Full Text] [Related]
6. Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome.
Marques-Pinheiro A; Levasseur R; Cormier C; Bonneau J; Boileau C; Varret M; Abifadel M; Allanore Y
Joint Bone Spine; 2010 Mar; 77(2):151-3. PubMed ID: 20096619
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG).
Laine CM; Chung BD; Susic M; Prescott T; Semler O; Fiskerstrand T; D'Eufemia P; Castori M; Pekkinen M; Sochett E; Cole WG; Netzer C; Mäkitie O
Eur J Hum Genet; 2011 Aug; 19(8):875-81. PubMed ID: 21407258
[TBL] [Abstract][Full Text] [Related]
8. A novel mutation in the LRP5 gene is associated with osteoporosis-pseudoglioma syndrome.
Barros ER; Dias da Silva MR; Kunii IS; Hauache OM; Lazaretti-Castro M
Osteoporos Int; 2007 Jul; 18(7):1017-8. PubMed ID: 17437160
[No Abstract] [Full Text] [Related]
9. A mutation in the signal sequence of LRP5 in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats.
Chung BD; Kayserili H; Ai M; Freudenberg J; Uzümcü A; Uyguner O; Bartels CF; Höning S; Ramirez A; Hanisch FG; Nürnberg G; Nürnberg P; Warman ML; Wollnik B; Kubisch C; Netzer C
Hum Mutat; 2009 Apr; 30(4):641-8. PubMed ID: 19177549
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
Ferrari SL; Deutsch S; Antonarakis SE
Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
[TBL] [Abstract][Full Text] [Related]
11. Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray.
Narumi S; Numakura C; Shiihara T; Seiwa C; Nozaki Y; Yamagata T; Momoi MY; Watanabe Y; Yoshino M; Matsuishi T; Nishi E; Kawame H; Akahane T; Nishimura G; Emi M; Hasegawa T
Am J Med Genet A; 2010 Jan; 152A(1):133-40. PubMed ID: 20034086
[TBL] [Abstract][Full Text] [Related]
12. A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene.
Cheung WM; Jin LY; Smith DK; Cheung PT; Kwan EY; Low L; Kung AW
Bone; 2006 Sep; 39(3):470-6. PubMed ID: 16679074
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment.
Tüysüz B; Bursalı A; Alp Z; Suyugül N; Laine CM; Mäkitie O
Horm Res Paediatr; 2012; 77(2):115-20. PubMed ID: 22456437
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis-pseudoglioma syndrome in four new patients: identification of two novel LRP5 variants and insights on patients' management using bisphosphonates therapy.
Abdel-Hamid MS; Elhossini RM; Otaify GA; Abdel-Ghafar SF; Aglan MS
Osteoporos Int; 2022 Jul; 33(7):1501-1510. PubMed ID: 35106624
[TBL] [Abstract][Full Text] [Related]
15. Treatment and management of osteoporosis-pseudoglioma syndrome.
Levasseur R
Expert Rev Endocrinol Metab; 2008 May; 3(3):337-348. PubMed ID: 30754200
[TBL] [Abstract][Full Text] [Related]
16. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation.
Rickels MR; Zhang X; Mumm S; Whyte MP
J Bone Miner Res; 2005 May; 20(5):878-85. PubMed ID: 15824861
[TBL] [Abstract][Full Text] [Related]
17. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass.
Ren N; Lv S; Li X; Shao C; Wang Z; Mei Y; Yang W; Fu W; Hu Y; Sha L; Hu W; Zhang Z; Wang C
Osteoporos Int; 2024 Apr; ():. PubMed ID: 38625381
[TBL] [Abstract][Full Text] [Related]
18. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
[TBL] [Abstract][Full Text] [Related]
19. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.
Korvala J; Jüppner H; Mäkitie O; Sochett E; Schnabel D; Mora S; Bartels CF; Warman ML; Deraska D; Cole WG; Hartikka H; Ala-Kokko L; Männikkö M
BMC Med Genet; 2012 Apr; 13():26. PubMed ID: 22487062
[TBL] [Abstract][Full Text] [Related]
20. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]